



8 March 2024

ASX ANNOUNCEMENT

Control Bionics Announces Registration of NeuroNode™ with the UK Medicines and Healthcare Products Regulatory Agency

Melbourne, Australia – March 8, 2024 - Control Bionics, a leading innovator in assistive technology solutions, is pleased to announce that its flagship product, the NeuroNode™, has been successfully registered with the UK Medicines and Healthcare Products Regulatory Agency (MHRA). This registration is an important step as the business continues to further its strategy to sell NeuroNode as an unbundled accessory.

The NeuroNode has had CE mark registration in Europe for some time, and now with MHRA registration, the NeuroNode can be sold directly into both the UK and Europe.

The NeuroNode™ is a revolutionary wearable electromyography (EMG) device that enables individuals with limited or no physical movement to control computers, communication devices, and other assistive technologies using subtle muscle signals. By registering the NeuroNode™ with the MHRA, Control Bionics reaffirms its dedication to meeting the highest standards of safety, efficacy, and regulatory compliance in the United Kingdom.

"We are thrilled to receive regulatory approval for the NeuroNode™ from the UK Medicines and Healthcare Products Regulatory Agency," said Jeremy Steele, CEO of Control Bionics. "We are in discussions with a number of parties in the UK and Continental Europe about partnering with them for the sale of the NeuroNode into the broader European market." Mr Steele also added "The European market is very supportive of providing innovative and impactful technology in the Assistive Technology space. Last year we announced our intention to expand our NeuroNode only sales outside of our existing markets and this approval is an important part of this strategy."

The NeuroNode™ offers a non-invasive and intuitive solution for individuals with conditions such as spinal cord injuries, ALS (amyotrophic lateral sclerosis), cerebral palsy, and stroke, among others. Its advanced sensor technology and machine learning algorithms enable precise and reliable control, allowing users to type, navigate, and communicate with ease.

For more information about Control Bionics and the NeuroNode™, please visit www.controlbionics.com

This announcement was authorised by CBL CEO, Jeremy Steele.

About Control Bionics:

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by diseases such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts like the mouse button. Control Bionics offers the only such product to harness three modalities — touch, eye and NeuroNode



control — which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. DROVE allows powered users the independence to operate their wheelchairs in their own homes for the first time.

In October 2023 Control Bionics announced the launch of its next generation NeuroNode device, the NeuroStrip. The ultra-lightweight device features a direct-to-skin electrode which has comprehensive physiological telemetry and is a material advancement on the NeuroNode. NeuroStrip has a range of potential new applications in disability, medtech, and consumer markets.

Control Bionics operates in North America, Australia, Singapore, and Japan.